Odyssey – Talk Bio

Odyssey Therapeutics Secures $213M Series D to Accelerate Autoimmune Clinical Portfolio

1 day ago talkbio0Tagged Autoimmune Diseases, clinical pipeline, Immunoregulation, Inhibitor, investors, Odyssey, Precision - temporal, preclinical programs, Protac, RIPK2, Series D financing, Technology

Odyssey Therapeutics; Series D financing; $213 million; autoimmune diseases; clinical pipeline; preclinical programs; precision immunomodulation; RIPK2 inhibitor; PROTAC technology; investors

Odyssey Therapeutics Abandons IPO Plans in Latest Sign of Tough Environment for Biotech Listings

3 months ago talkbio0Tagged Autoimmune, IPO, Market, Odyssey, seconds, turbulence, Withdraw (activity)

Odyssey Therapeutics; IPO; biotech; withdrawal; SEC; market turbulence; autoimmune

Sionna and Odyssey Therapeutics Kick Off 2025 Biotech IPO Wave with SEC Filings

8 months ago talkbio0Tagged 2025, File (record), Health care facility, Industry, IPO, JPM, Market, Odyssey, Sionna

Sionna Therapeutics, Odyssey Therapeutics, IPO filings, biotech industry, JPM Healthcare Conference, 2025 IPO market